ProBiotix Health, an OptiBiotix Health PLC subsidiary company, launched a tri-layer tablet, CholBiomeBP, that combines four science-backed ingredients to support hypertension and cardiovascular health.
Image courtesy of ProBiotix Health
ProBiotix Health, an OptiBiotix Health PLC subsidiary company based in the United Kingdom, launched a tri-layer tablet, CholBiomeBP, that combines four science-backed ingredients to support hypertension and cardiovascular health, including the company’s probiotic strain LPLDL, thiamine (vitamin B1), the amino acid L-arginine, and coenzyme Q10 (CoQ10).
“We are thrilled to launch CholBiomeBP as part of the CholBiome brand portfolio,” said Mikkel Hvid-Hansen, commercial director at ProBiotix, in a press release. “CholBiomeBP is a natural food supplement that, by combining all four ingredients together in a unique way, helps to support normal cardiac function, as recognized by the European Food Safety Authority (EFSA).”
According to ProBiotix Health, in an independent, 12-week human study featuring 40 adults with high blood pressure, CholBiomeBP decreased diastolic blood pressure and reduced systolic blood pressure. In addition, the supplement also decreased low-density lipoprotein (LDL) cholesterol and total cholesterol.
“We’re pleased to announce that CholBiomeBP will be joining the OptiBiotix Online store and will be complementing our growing science-backed cardiovascular health range,” said Steven Riley, director of marketing and consumer sales at OptiBiotix, in a press release. “The blood pressure reducing supplement is a key part of our commercial growth and is an exciting step forward to support consumers on their journey towards a healthier lifestyle.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.